Opendata, web and dolomites

BRIGHT

40 Hz Masked Light: A new venture to slow the progression of Alzheimer’s Disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BRIGHT project word cloud

Explore the words cloud of the BRIGHT project. It provides you a very rough idea of what is the project "BRIGHT" about.

approximately    fusion    decades    industrial    prior    triggers    core    while    patent    avoiding    clinical    route    off    liaise    leverage    roadblocks    33    minimizing    bright    dementia    market    founding    ahead    leds    representing    full    disease    formed    cascade    maturation    light    combinations    colour    stroboscopic    fadigue    productization    wavelengths    invasive    players    cortex    demonstration    appropriate    company    receptors    sizeable    alternating    serving    savings    risk    amyloid    neuro    devised    patients    drugs    100bn    significantly    de    certification    later    delay    reduce    stages    setup    variants    shows    prepare    visual    appear    led    brain    intervention    global    optimal    stone    prevalence    inducing    protected    optoceutics    protective    experiencing    colours    primarily    coloured    vital    accentuates    promotes    untap    beta    flashing    capturing    strategy    stepping    believe    irreversible    white    onset    ad    blue    ing    alzheimer    alone    human    stimulate    roll    frequency    neurodegenerative    flickering    business    instead    clearance    hz    pandemic    improvements    members    accumulation    damage   

Project "BRIGHT" data sheet

The following table provides information about the project.

Coordinator
OPTOCEUTICS APS 

Organization address
address: DIPLOMVEJ 381
city: KONGENS LYNGBY
postcode: 2800
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website http://www.optoceutics.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OPTOCEUTICS APS DK (KONGENS LYNGBY) coordinator 50˙000.00

Map

 Project objective

While Alzheimer’s Disease (AD) is a global pandemic, it has been estimated that a five-year delay in the disease onset could reduce the disease prevalence – and its costs – by up to 33% over the next decades, representing potential savings over €100bn in EU alone. However, there are still significant roadblocks ahead as current drugs do not untap sizeable improvements in AD patients. This is primarily due to the challenge of minimizing the impact of irreversible brain damage in later dementia stages, which accentuates the need for early intervention. However, recent evidence shows that non-invasive flashing (stroboscopic) light at the appropriate frequency (40 Hz) promotes clearance of beta-amyloid – whose accumulation is believe to be one of the key triggers to the neurodegenerative cascade leading to dementia states.

Instead of using fadigue-inducing stroboscopic flashing light (i.e. on-off), the founding members of OptoCeutics have devised a unique, patent-protected method to stimulate the human visual receptors and processing cortex through alternating white light composed of different wavelengths. The two variants of the white light are formed by different combinations of coloured LEDs. When flickering between the two LED sets, the colours fusion together and appear as one, resulting in approximately the same white colour, avoiding experiencing light flashing, but the brain is capturing the blue component flashing with 40 Hz – thus still promoting neuro-protective beta-amyloid clearance.

OptoCeutics will leverage from BRIGHT as a vital stepping stone to prepare the company’s business strategy, serving also to significantly de-risk its route-to-market by enabling to liaise with major industrial and clinical players to define both the optimal productization and maturation of Optoceutics core technology, as well as the setup for its full-scale demonstration and certification, prior market roll-out.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRIGHT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BRIGHT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More  

DetectInMen (2019)

Infection detection in human semen

Read More  

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More